Pointe Capital Management LLC Buys Shares of 1,970 Illumina, Inc. (NASDAQ:ILMN)

Pointe Capital Management LLC bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,970 shares of the life sciences company’s stock, valued at approximately $263,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Versant Capital Management Inc grew its position in Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 146 shares during the last quarter. Golden State Wealth Management LLC purchased a new stake in shares of Illumina during the fourth quarter valued at $32,000. TD Private Client Wealth LLC boosted its stake in shares of Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after purchasing an additional 141 shares during the period. V Square Quantitative Management LLC grew its holdings in shares of Illumina by 50.6% in the fourth quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock worth $52,000 after purchasing an additional 132 shares during the last quarter. Finally, First Horizon Advisors Inc. increased its stake in Illumina by 73.5% in the 4th quarter. First Horizon Advisors Inc. now owns 439 shares of the life sciences company’s stock worth $59,000 after buying an additional 186 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ILMN has been the subject of several research reports. Canaccord Genuity Group lowered their price objective on shares of Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research report on Friday, February 7th. Barclays lowered Illumina from an “equal weight” rating to an “underweight” rating and lowered their price target for the company from $130.00 to $100.00 in a report on Monday, February 10th. Robert W. Baird increased their price objective on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. JPMorgan Chase & Co. lifted their target price on Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Finally, Morgan Stanley lowered their target price on Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a report on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $159.45.

Illumina Stock Performance

Shares of ILMN stock opened at $95.73 on Wednesday. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The company has a market cap of $15.16 billion, a PE ratio of -12.46, a PEG ratio of 1.60 and a beta of 1.10. Illumina, Inc. has a 12-month low of $91.92 and a 12-month high of $156.66. The business’s fifty day simple moving average is $126.02 and its 200-day simple moving average is $133.80.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.